Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2-CHOP for untreated bulky diffuse large B-cell lymphoma
ChiCTR1900026520Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine and 1 more in diffuse large B-cell lymphoma (DLBCL), sponsored by Affiliated Hospital of Nantong University. Primary endpoint: Overall response rate. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
lenalidomiderituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1900026520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026520.